ICATIBANT ACETATE Drug Patent Profile
Which patents cover Icatibant Acetate, and when can generic versions of Icatibant Acetate launch?
Icatibant Acetate is a drug marketed by Alembic, Caplin, Cipla, Eugia Pharma, Fresenius Kabi Usa, Glenmark Pharms Ltd, Jiangsu Hansoh Pharm, Nang Kuang Pharm Co, Teva Pharms Usa, and Wilshire Pharms Inc. and is included in ten NDAs.
The generic ingredient in ICATIBANT ACETATE is icatibant acetate. Nine suppliers are listed for this compound. Additional details are available on the icatibant acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Icatibant Acetate
A generic version of ICATIBANT ACETATE was approved as icatibant acetate by TEVA PHARMS USA on July 15th, 2019.
Paragraph IV (Patent) Challenges for ICATIBANT ACETATE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| FIRAZYR | Injection | icatibant acetate | 10 mg/mL | 022150 | 2 | 2015-08-25 |
